Company intelligence / Profile preview
BioConvergent Health
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
BioConvergent Health has a pipeline anchored by two Phase 2 drugs with clinical proof of concept, a cancer vaccination drug + ultrasound platform, and its lead program in non-small cell lung cancer is advancing toward Phase 2/3 registration. Additional programs are in oncology (combination regimens with radiation and drugs) and hematology (thrombocytopenia in low-risk myelodysplastic syndrome, Phase 2, FDA aligned).
- Therapeutic areas
- HematologyOncology
- Modalities
- Small moleculeDrug-device combinationRadiationUltrasound deviceCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Multiple global pharmaceutical companiesMultiple global device companiesAcademic medical institutions
Beyond the preview
Go deeper on BioConvergent Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioConvergent Health.